Shimada Ayako, Ohnaka Shinnosuke, Kubo Kosumi, Nakashima Masanao, Nagai Atsushi
Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, Kanagawa, JPN.
Cureus. 2022 Apr 2;14(4):e23755. doi: 10.7759/cureus.23755. eCollection 2022 Apr.
Remdesivir, dexamethasone, and baricitinib have recently been used to treat patients with coronavirus disease 2019 (COVID-19) and respiratory failure. However, the adverse effects of combination therapy have not been fully explored. A 64-year-old man was diagnosed with COVID-19 and was treated with remdesivir, dexamethasone, and baricitinib. His respiratory condition worsened on day 17, and in the following days, he was diagnosed with pneumomediastinum and COVID-19-associated pulmonary aspergillosis (CAPA). His condition improved with a reduction in the corticosteroid regime and antifungal treatment. This is the first case of pulmonary aspergillosis in a patient with COVID-19 that was treated with remdesivir, dexamethasone, and baricitinib.
瑞德西韦、地塞米松和巴瑞替尼最近被用于治疗2019冠状病毒病（COVID-19）和呼吸衰竭患者。然而，联合治疗的不良反应尚未得到充分研究。一名64岁男性被诊断为COVID-19，并接受了瑞德西韦、地塞米松和巴瑞替尼治疗。他在第17天呼吸状况恶化，随后几天，他被诊断为纵隔气肿和COVID-19相关肺曲霉病（CAPA）。随着皮质类固醇治疗方案的减少和抗真菌治疗，他的病情有所改善。这是首例在接受瑞德西韦、地塞米松和巴瑞替尼治疗的COVID-19患者中发生肺曲霉病的病例。
